VEGFR-2/KDR inhibitors (Cephalon)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameVEGFR-2/KDR inhibitors (Cephalon)
Drug Alias Namesemaxanib analogs (Cephalon)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor antagonists
TargetsVascular endothelial growth factor receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCephalon Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCephalon Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A